When standard Cephalosporins or Macrolides face resistance, FAROQS provides the clinical breakthrough needed for pediatric recovery.
Superior Stability: Resists hydrolysis by many beta-lactamases, ensuring the drug reaches the infection site intact.
High Tissue Penetration: Reaches therapeutic concentrations rapidly in the lungs, tonsils, and middle ear.
Patient Preference: A delicious flavor profile designed to eliminate "spit-ups" and ensure full dose compliance in children.
F - Fast Bactericidal Action
A - Advanced Penem Class
R - Resistant to beta-lactamase
O - Oral Convenience
Q - Quality Recovery
S - Superior Safety Profile
FAROQS is highly effective against both aerobic and anaerobic pathogens:
Respiratory: S. pneumoniae, H. influenzae, M. catarrhalis
Urinary: E. coli, Klebsiella spp.
Skin: S. aureus, S. pyogenes
| Age Group | Weight (Approx) | Dosage (per day) |
|---|---|---|
| Infants / Children | 15MG--30MG/KG | Divided into 3 doses |